In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...
Zacks.com on MSN16h
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's ImfinziJohnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...
The U.K. government is defending its negotiations with AstraZeneca (AZN), after the pharmaceutical company dropped a planned $558M investment ...
AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...
(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a ...
HHM Wealth Advisors LLC grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 38.8% during the 4th ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback